Jessica Hergert | Authors

Articles

Second-Line Pembrolizumab Shows Continued OS and PFS Improvement in Advanced HCC

January 18, 2021

In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.